Exploring innovations in AAV upstream processing to advance gene therapy development
Cell & Gene Therapy Insights 2025; 11(4), 483–487
DOI: 10.18609/cgti.2025.058
Published: 8 May
Interview
Hao Liu
“...my goal is to introduce innovative designs and new concepts to the AAV manufacturing field.”
Jokūbas Leikauskas, Editor, Cell & Gene Therapy Insights, speaks toHao Liu, Viral Vector Core Research Associate III, Horae Gene Therapy Center, UMass Chan Medical School, about addressing the challenges in viral vector upstream processing with novel AAV manufacturing platforms to boost vector purity, reduce costs, and support the broader mission of advancing gene therapies from research to clinical application.